Tuesday, October 7


Tuesday, October 7

(The presenters of gray titles did not allow the online appearance of their lectures )


22. MOLECULAR AND CELLULAR BIOLOGY OF CANCER

ROOM A, 08.00-12.00 – Tuesday, October 7

Chair Persons: R.M. Hoffman, F.E. Ahmed, P. Kumar


23. HOX GENES IN CANCER
Special Symposium Organized by C. Aukim-Hastie and R. Morgan

ROOM A, 13.00-16.20 – Tuesday, October 7

Chair Persons: R. Morgan, C. Aukim-Hastie

  • Introduction: R. Morgan(10’)
  • HOX transcription factors are potential targets and markers in malignant mesothelioma. R. Morgan, S. Gray, C. Gillett, Z. Tabi, F. Launchbury, J. Spicer, K. Harrington, H.S. Pandha (Guilford; London; Cardiff, UK) (20’)
  • HOX genes in head and neck squamous cell carcinoma (HNSCC). K.D. Hunter (Sheffield, UK) (20’)
  • Targeting the HOX transcription factors and CD71 in multiple myeloma. T.R. Daniels, I.I. Neacato, J.A. Rodríguez, H.S. Pandha, R. Morgan, M.L. Penichet (Los Angeles, CA, USA; Guildford, UK) (20’)
  • Giving birth to blood stem cells, in vitro: HOXB4 promotes hematopoiesis during pluripotent stem cell differentiation by increasing the pool of hemogenic endothelium cells. N. Teichweyde, L.Kasperidus, S. Skibbe, P. Horn, H. Klump (Essen, Germany) (20’)
  • Investigating the role of homeobox genes in breast cancer stem cell function. M. Shah, R. Emes,A. Grabowska, C. Allegrucci (Loughborough; Nottingham, UK) (20 ‘)
  • Candidate drug screening in HOX-related models of AML. C.L. Burt, L.M.J. Kettyle, N.M. Mulgrew, J.M. Ramsey, G.J. Dickson, A. Thompson (Belfast; London, UK) (20’)
  • The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the MIR-221&222-C-FOS pathway. M.C. Errico, F. Felicetti, L. Bottero, G. Mattia, N. Felli, M. Petrini, M. Bellengh, H.S. Pandha, R. Morgan, A. Carè(Rome, Italy; Guilford, UK) (20’)
  • HOX gene expression in ovarian cancer. A. Michael, Z.L. Kelly, C.S. Moller-Levet, H. Pandha, R. Morgan (Guildford,UK) (20’)
  • Closing remarks : R. Morgan(5’)

24. ONCOGENES; TUMOR SUPPRESSOR GENES; GROWTH FACTORS; SIGNAL TRANSDUCTION

ROOM A, 16.30-19.45 – Tuesday, October 7

Chair Persons: T.G. Cotter, R. Todorova


25. SERUM MARKERS IN DIAGNOSIS AND THERAPY
ISOBM. Special Symposium Organized by R. Molina and V. Barak

ROOM B, 8.00-10.00 – Tuesday, October 7

Chair Persons: R. Klapdor, R. Molina, V. Barak

  • Comparison of 3 different immunoassays for determination of CA 19-9 in pancreatic cancer patients – a new aspect of potentially clinical relevance. R. Klapdor, M. Bahlo (Hamburg, Germany) (20’)
  • Tumor markers in lung cancer, a tool for early diagnosis? R. Molina, R.M. Marrades, J.M. Augé, J.M. Escudero, N. Viñolas, N. Reguart, J. Ramirez, X. Filella, L. Molins, A. Agusti (Barcelona,Spain) (30’)
  • Prognostic significance of tumor markers in breast cancer. V. Barak, B. Uziely, A. Hubert, I. Kalichman, R. Einarsson, T. Peretz (Jerusalem, Israel) (30’)
  • Liquid biopsy – new perspectives for prediction and monitoring of therapy response in cancer patients. S. Holdenrieder (Bonn, Germany) (30’)

26. SERUM MARKERS IN DIAGNOSIS AND THERAPY

ROOM B, 10.10-12.00 – Tuesday, October 7

Chair Persons: R. Klapdor, S. Holdenrieder, V. Barak

  • Biomarkers for malignant melanoma –treatment response assessment and metastasis prediction. V. Barak, S. Frenkel, S. Merims, M. Lotem, T. Peretz, I. Kalichman, J. Pe’er (Jerusalem, Israel) (30′)
  • Histone modifications in circulating nucleosomes as potential new biomarkers in cancer. U. Gezer, E.E. Yörüker, M. Keskin, S. Holdenrieder, N. Dalay (Istanbul, Turkey) (15’)
  • Roles of caveolin-1 and cyclooxygenase 2 in kidney, ureter, bladder and prostate cancers. W.-S. Chang, C.-W. Tsai, C.-M. Hsu, D.-T. Bau (Taichung, Taiwan) (15’)
  • Practical experience of the fecal hemoglobin immunochemical test in a colorectal cancer screening program. J.M. Auge (Barcelona, Spain) (30’)
  • Determination of neopterin, kynurenine and tryptophan as immune system activation markers in various biological fluids. L. Kujovská Krcmová, B. Cervinková, D. Solichová, B. Melichar, L. Sobotka, P. Solich (Králové, Czech Republic) (15’)

27. SERUM MARKERS IN DIAGNOSIS AND THERAPY

ROOM B, 13.00-15.00 – Tuesday, October 7

Chair Persons: K.J. Syrjänen, O. Topolcan


28. IMAGE-GUIDED RADIOTHERAPY
Special Symposium of the International Geriatric Radiotherapy Group (IGRG)
Organized by N.P. Nguyen

ROOM B, 15.15-19.00 – Tuesday, October 7

Chair persons: N.P. Nguyen, U. Karlsson

  • Elderly and cancer care. U. Karlsson (Marshfield, WI, USA)(40’)
  • The role of image-guided radiotherapy in dose escalation for locally advanced non-small cell lung cancer. A. Chi, N.P. Nguyen (Morgantown, WV, USA) (30’)
  • Treatment planning comparison between HDR & IMRT for early stage breast cancer using SAVI technique. S.R. Bose, N.P. Nguyen (Washington, DC, USA) (30’)
  • The potential of image-guided radiotherapy for normal organs sparing in patients with locally advanced head and neck cancer. N.P Nguyen, A. Chi, V. Vinh-Hung, O. Gorobets, S. Bose, U. Karlsson (Washington, DC, USA) (25’)
  • Feasibility of image-guided radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. N.P. Nguyen, S. Kratz, A. Chi, J. Vock, P. Vos, W. Shen, V. Vinh-Hung, L. Ewell, S. Jang, G. Altdorfer, U. Karlsson, J. Godinez, W. Woods, S. Dutta, F. Ampil (Washington, DC; Tucson, AZ; Morgantown; Parkersburg, WV; Greenville, NC; Marshfield, WI; Jacksonville, FL; Salisbury, MD; Shreveport, LA; San Antonio, TX, USA; Martinique, France; Lindenhofspital, Switzerland) (25’)
  • Studies on human cells irradiated with two radiation modalities (IMRT or conventional RT) show different molecular and cellular responses: public health implications. F.E. Ahmed, P.W. Vos, R.R. Allison, C. Jeffries (Greenville; Chapel Hill, NC, USA) (30’)

29. EXPERIMENTAL CHEMOTHERAPY

ROOM C, 08.00-12.15 – Tuesday, October 7

Chair Persons: G. Ciarimboli, J. Haybaeck


30. CYTOGENETICS AND GENETICS

ROOM C, 13.00-15.30 – Tuesday, October 7

Chair Persons: D.-T. Bau, E. De Breakeleer, S. Ingvarsson

  • BAC analysis of chromosomal translocation breakpoints: an efficient strategy for identifying new candidate genes in malignant hemopathies. N. Douet-Guilbert, E. De Breakeleer, C. Tous, N. Gueganic, M.J. Le Bris, A. Basinko, M. De Braekeleer (Brest, France) (30’)
  • The genetic landscape of familial breast cancer in Iceland. S. Ingvarsson (Reykjavik, Iceland) (30’)
  • Identification of PRRC1-MLL, a novel fusion gene, in a case of therapy-related acute lymphoblastic leukemia. N. Douet-Guilbert, C. Meyer, J.R. Eveillerd, V. Ugo, M.J. Le Bris, A. Basinko, F. Morel, R. Marschalek, M. De Braekeleer (Brest, France; Mail, Germany) (15’)
  • Effects of Ataxia telangiectasia mutated (ATM) genotypes and personal smoking status on lung cancer risk in Taiwan. S.-C. Wang, W.-S. Chang, C.-M. Hsu, C.-W. Tsai, D.-T. Bau (Taichung, Taiwan, ROC) (15’)
  • Evaluation of the contribution of methylenetetrahydrofolate reductase genotypes to Taiwan breast cancer. C.-Y. Huang, W.-S. Chang, C.-W. Tsai, C.-M. Hsu, C.-L. Hsiao, D.-T. Bau (Taichung; Taipei, Taiwan, ROC) (10’)
  • The genotype/phenotype study for the role of caveolin-1 in gastrointestinal tract cancers. C. M. Hsu, W.-S. Chang, H.-X. Ji,C.-W. Tsai, D.-T. Bau (Taichung, Taiwan, ROC) (20’)

31. CARCINOGENESIS

ROOM C, 15.45-19.10 – Tuesday, October 7

Chair Persons: G.R. Rutteman, H.C.R. Wang

  • Reactive oxygen species-mediated breast cell carcinogenesis enhanced by chronic exposure to multiple carcinogens and intervened by dietary agents. H.C.R. Wang, L.A. Pluchino (Knoxville, Tennessee, USA) (40’)
  • Helicobacter pylori: Multitalented adaptation of binding properties. T. Borén (Umea, Sweden) (40’)
  • Molecular biological and genetic investigations of cancers in companion animals can provide important insight in (rare) cancers in the human. G.R. Rutteman (Utrecht; Wageningen, The Netherlands) (30’)
  • The role of the ECL cell in gastric carcinogenesis. H.L. Waldum, Ø. Hauso, Ø. Sørdal, R. Fossmark (Trondheim, Norway)(20’)
  • A preliminary mutagenesis study of camphor in human leukocytes culture. J.C. Santos, M.F. Bellini (Bauru, Brazil) (30’)
  • Silver nanoparticles increase the ionic permeability of the pleura and partially inhibit the migration of pleural mesothelial cells. V. Arsenopoulou, P.A. Molyvdas, K. Gourgoulianis, C. Hatzoglou, S.G. Zarogiannis (Larissa, Greece) (10’)

32. MICROENVIROMENTAL HETEROGENEITY OF BRAIN TUMOURS: DYNAMIC TOPOGRAPHICAL CHANGES AND ADAPTATION TO THERAPIES
Special Symposium Organized by G. Pilkington and H. Fillmore

ROOM D, 8.00-15.30 – Tuesday, October 7

Chair Persons: C. Herold-Mende, H. Fillmore, G. Pilkington

Part 1. Microenvironmental drivers of glioma heterogenecity and therapeutic resistance: Antiogenesis
Chair Person: C. Herold-Mende

  • Adaptive mechanisms to anti-vascular therapy. R. Bjerkvig (Bergen, Norway) (30’)
  • The perivascular glioma niche and its role in therapeutic resistance: safe harbour or active participant? H. Fillmore (Portsmouth, UK) (30’)

Part 2: Microenvironmental drivers of therapeutic resistance: Immune-mediated resistance
Chair Person: H. Fillmore

  • Contribution of the immunological microenvironment on GBM survival. C. Herold-Mende (Heidelberg, Germany)(30’)
  • Mesenchymal stem cells affect glioblastoma cells upon direct contact. H. Motaln, J. Schuchhard, K. Stec, B. Breznik, H. Ulrich, T.T. Lah (Sao Paulo, Brazil; Ljublijana, Slovenia) (30’)
  • Paradoxical role of mesenchymal stem cells in glioblastomas microenvironment. H. Motaln, J. Schuchhardt, K. Stec, B. Breznik, H. Ulrich and T.T. Lah (Potsdam; Berlin, Germany; Sao Paulo, SP, Brazil; Ljublijana, Slovenia) (20’)

Part 3. Post-doctoral and student presentations (10 min + 5 min discussion)
Chair Person: G. Pilkington

  • T cell target repertoire in primary and recurrent glioblastomas. C. Rapp, R. Warta, S. Stamova, P. Beckhove, M. Schnölzer, C. Herold-Mende (Heidelberg, Germany) (10’)
  • Mitochondrial DNA mutations and brain tumour heterogeneity: Insights from three dimensional structural analysis. K. Keatley, R.E Lloyd, Q. An, H.L. Fillmore, G. J. Pilkington, J.E. McGeehan (Portsmouth, UK) (10’)
  • CD15 and E-selectin mediate adhesion of non-small cell lung cancer cells to brain endothelium. S.A. Jassam, Z. Maherally, J. Smith, K. Ashkan, H.L. Fillmore and G.J. Pilkington (Portsmouth, UK) (10’)
  • Trick or treat: Impact of the microenvironment on the infiltration of T-cells in lower grade gliomas. S. Dettling, A. Moch, C. Geinsenberger, L. Hartmann L, A. von Deimling A, C. Herold-Mende (Heidelberg, Germany) (10’)
  • Deacetylation of GD3A as a potential therapeutic strategy for paediatric medulloblastoma. R. Mather, K. Stephenson, H.L. Fillmore, G.J. Pilkington (Portsmouth, UK) (10’)

Part 4. Microenvironmental impact on the cross-talk between glioma cells, immune cells and antiogenesis in glioblastoma: Potential combinational targets (Round table discussion)
Chair persons: H. Fillmore, C. Herold-Mende, R. Bjerkvig , G. Pilkington

  • Experimental questions/design to explore potential micro-environmental therapeutic targets; Challenges and EU collaborative proposals (ie. COST)

33. IMMUNOTHERAPY; BIOTHERAPY; VACCINES

ROOM D, 15.45-19.10 – Tuesday, October 7

Chair persons: F. Guadagni, K. Hellstrand, J. Koch


34. CHEMOPREVENTION. ENVIRONMENTAL EXPOSURE AND CANCER RISK

ROOM E, 8.00-12.00 – Tuesday, October 7

Chair Persons: W. Weber, B. Davidson


35. BREAST CANCER: PATHOLOGY AND IMAGING
Special Symposium Organized by N.J. Agnantis

ROOM E, 13.00-15.00 – Tuesday, October 7

Chair Persons: N.J. Agnantis
Round Table

Discussion(10’)


36. CANCER STEM CELLS
Special Symposium Organized by M. Jhanwar-Uniyal, G. Sica

ROOM E, 15.15-19.00 – Tuesday, October 7

Chair Persons: G. Sica, M. Jhanwar-Uniyal


37. NEW INSIGHTS IN RENAL CANCER
Special Symposium of SIUrO Organized by G. Sica and G. Conti

ROOM F, 8.00-14.00 – Tuesday, October 7

Chair Persons: G. Sica, G. Martorana
Welcome address by Giario Conti, SIUrO President

Conclusion : G. Conti


38. MULTI-DRUG AND DRUG RESISTANCE: MECHANISMS AND REVERSAL

ROOM F, 14.15-16.15 – Tuesday, October 7

Chair Person: L. Amaral, G. Giamas


39. NEW ANTICANCER AGENTS

ROOM F, 16.30-19.30 – Tuesday, October 7

Chair Persons: A. Bhushan, H.M. Warenius

  • Tyrosine phosphorylation: Role in antifolate resistance. A. Bhushan, T. Liu, P. Sheridan and J.C.K. Lai (Philadelphia, PA, USA) (30’)
  • Global anticancer targets: still a possibility? H.M. Warenius (Southampton, UK) (30’)
  • Brk/PTK6 as a novel therapeutic target in breast cancer. R.S. Burmi, G.A. Box, C.J. Pennington, J.A. Davies, W.J. Court, S.A. Eccles, D.R. Edwards, A. Harvey (Uxbridge, UK) (30’)
  • Identification and design of new C5-DNA methyltransferase inhibitors and their biological activity. P.B. Arimondo (Toulouse, France) (30’)
  • Exploiting the potential of lipids and frogs foams to treat Cancer. D.A. Lamprou (Glasgow, Scotland, UK) (20’)
  • Initial evaluation of a CD146/MUC18 targeting radioimmunoconjugate. S. Westrøm, N. Abbas, R.H. Larsen, O.S. Bruland, T.J. Jonasdottir, T.B. Bønsdorff (Oslo, Norway) (10’)